Nodular Lymphocyte Predominant B-Cell Lymphoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Nodular Lymphocyte Predominant B-Cell Lymphoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT05886036

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-P…

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lym…

United States70 participantsStarted 2024-01-23

Treatment: Biopsy Procedure, Biospecimen Collection

All recent trials (9 shown)

Active — Not RecruitingPhase 2/3

NCT04799275

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diff…

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cycloph…

United States422 participantsStarted 2021-05-20

Treatment: Biospecimen Collection, Computed Tomography

Active — Not RecruitingPhase 2

NCT00107198

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young pa…

United States188 participantsStarted 2006-01-02

Treatment: Conventional Surgery, Cyclophosphamide

Nodular Lymphocyte Predominant B-Cell Lymphoma

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-P…

All recent trials (9 shown)

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diff…

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-P…

All recent trials (9 shown)

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diff…

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Ste…

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refra…

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma